Novartis raises core profit guidance despite a $1.9 billion impairment
Novartis third-quarter sales rose 4% and core margin reached 41.6%. Reported operating and net income fell sharply due to a $1.9 billion impairment.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Novartis reported that third-quarter sales rose 4%, while its core margin widened to 41.6%. On this basis, the company raised its full-year guidance for core operating income. Reported operating and net income, however, fell sharply because of a $1.9 billion impairment linked to the del-desiran asset. The information comes from TradingView, which based its report on an AI-generated summary of the results.
why it matters
For investors, the key point is that underlying profitability looks stronger, while the drop in reported earnings stems from a one-off write-down. Margin trends and the updated outlook typically matter more for valuing the shares than the accounting loss itself.
market impact
Novartis and the SMI index: stronger core margin and higher guidance support the shares, while the impairment weighs on reported earnings
tags
instruments
sources
- NOVN: Q3 growth and wider core margins lifted FY guidance despite a $1.9B impairment — TradingView, 27 October 2026 at 06:02 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗